Fingolimod-induced immune thrombocytopenic purpura (ITP)

Clin Neurol Neurosurg. 2020 Oct:197:106081. doi: 10.1016/j.clineuro.2020.106081. Epub 2020 Jul 10.

Authors

Loulwah Mukharesh¹, Ted L Rothstein²

Affiliations

¹ Johns Hopkins University School of Medicine, Department of Neurology, Baltimore, MD, United States; George Washington University, Department of Neurology, Washington, DC, United States. Electronic address: lmukhar1@jhmi.edu.
² George Washington University, Department of Neurology, Washington, DC, United States. Electronic address: trothstein@mfa.gwu.edu.

PMID: 32739722
DOI: 10.1016/j.clineuro.2020.106081

No abstract available

Keywords: Drug-induced immune thrombocytopenic purpura; Fingolimod; Immune-thrombocytopenic purpura; Multiple sclerosis; Neurology.

Publication types

Case Reports

MeSH terms

Adult
Fingolimod Hydrochloride / adverse effects*
Glucocorticoids / therapeutic use
Humans
Immunoglobulins, Intravenous / therapeutic use
Methylprednisolone / therapeutic use
Middle Aged
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Multiple Sclerosis, Relapsing-Remitting / immunology
Purpura, Thrombocytopenic, Idiopathic / chemically induced*
Purpura, Thrombocytopenic, Idiopathic / drug therapy
Purpura, Thrombocytopenic, Idiopathic / immunology
Sphingosine 1 Phosphate Receptor Modulators / adverse effects*
Treatment Outcome

Substances

Glucocorticoids
Immunoglobulins, Intravenous
Sphingosine 1 Phosphate Receptor Modulators
Fingolimod Hydrochloride
Methylprednisolone